Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05268107 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ethnic Differences in Mechanisms of Action of Dupilumab

StatusRecruiting
PhasePhase 4
Started2023-01-25
View on ClinicalTrials.gov ↗

Amendment history

2025-11-04
Study Status, Oversight v7
Primary completion date2025-12→2026-12
Completion date2026-06→2027-06
2024-11-26
Study Status, Oversight v6
Primary completion date2024-12→2025-12
Completion date2025-06→2026-06
2023-12-18
Study Status v5
Primary completion date2023-12→2024-12
Completion date2024-04→2025-06
2023-01-27
Study Status v4
Start dateestimated 2023-01→confirmed 2023-01-25
2022-12-22
Study Status v3
Start date2022-10→2023-01
Show 2 earlier versions
2022-09-07
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start date2022-05→2022-10
Study sitesdetails revised at 1 of 1 site
2022-04-13
Study Status, Sponsor/Collaborators v1
Start date2022-03→2022-05
2022-03-04
Original filing
Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD. This trial will determine differences in inflammatory responses to dupilumab between Caucasian, Asian, and African American patients with AD. The central hypothesis of this study is that ethnic differences in both immune and stromal cells contribute to variability in AD presentation and response to anti-interleukin-4 receptor (IL-4R) inhibition with dupilumab.
Trial Details
NCT Number NCT05268107
Lead Sponsor University of Michigan
Collaborators: Regeneron Pharmaceuticals
Conditions Atopic Dermatitis
Enrollment 30 participants
Start Date 2023-01-25
Primary Completion 2026-12 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2025-11-06